Services on Demand
Journal
Article
Related links
Share
Revista Médica del Uruguay
Print version ISSN 0303-3295On-line version ISSN 1688-0390
Abstract
MALVASIO, Silvina et al. BRCA1 tumor expression and clinical results in uruguayan patients diagnosed with breast cancer before the age of 40 years old. Rev. Méd. Urug. [online]. 2020, vol.36, n.1, pp.123-152. Epub Mar 01, 2020. ISSN 0303-3295. https://doi.org/10.29193/rmu.36.1.6.
BRCA1 mutations are rare in sporadic breast cancer (CM), however their expression at the tumor level is diminished or absent in 30-50% of cases.
Objective:
to assess the tumor expression of BRCA1 using immunohistochemistry (IHC) in Uruguayan women diagnosed with BC before the age of 40 years.
Material and methods:
patients diagnosed with BC before the age of 40 between. The antibodies used were anti BRCA1 MS110 monoclonal antibodies against the N-terminal end and GLK-2 against the C-terminal. Overall survival (OS) and disease free survival (DFS) were calculated; the curves were developed using the Kaplan-Meier method and the difference in survival was evaluated through the log rank test.
Results:
the average age of the 40 patients included was 36 years. The 5-year OS and DFS were 73% and 60% respectively. The expression of BRCA1 with GLK-2 was <10% in 16 of the 40 patients included (40%). The 5-year OS and DFS for patients with <10% expression was 56% vs. 85% for patients with >10% (p=0.015) and 40% vs. 72% (p = 0.034) respectively. The expression of BRCA1 by MS110 was <10% in 11 of the 40 patients included (27.5%). No differences were found in the 5-year OS or DFS based on the expression of this marker.
Conclusion:
The loss of BRCA1 expression using GLK-2, which suggests the presence of a truncated protein, was associated with a statistically significantly lower OS and DFS, that the decrease in the BRCA1 protein as determined by GLK2 has an unfavorable prognostic value for young patients with BC.
Keywords : Breast neoplasms; BRCA1 genes; Immunohistochemistry; Young women.